Bath & Body Works Inc vs Mesoblast Limited — how do they compare? Bath & Body Works Inc trades at $18.67 (market cap $3.81B), while Mesoblast Limited trades at $17.03 (market cap $2.21B). The key difference: Bath & Body Works Inc is the larger of the two by market cap, and Bath & Body Works Inc pays a 4.24% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| BBWI | MESO | |
|---|---|---|
Market Cap | $3.81B | $2.21B |
Sector | Consumer Cyclical | Technology |
52-Week High | $31.87 | $20.96 |
52-Week Low | $14.85 | $12.88 |
Enterprise Value | $7.70B | $2.21B |
Dividend Yield | 4.24% | — |
Signals from Pluang's Aura AI — not financial advice
BBWI trades at $19.32, down 5.11% over 24 hours, with a bearish technical signal and key support at $19. The stock shows attractive valuation metrics, including a P/E of 5.36 and P/S of 0.54, with a net income margin of 10.03% for 2025. Recent developments include expansion into Brazil and a partnership with Ulta Beauty, while Q2 2026 earnings are anticipated on August 26, 2026.
The outlook presents a value opportunity given low valuations and strategic growth initiatives, but risks include declining revenue trends, high debt levels, and negative shareholder equity. Analyst consensus is mixed with a $22.11 price target, suggesting potential upside if turnaround efforts succeed amidst competitive and execution challenges.
No Aura AI signal available yet.
Trailing returns across standard periods
Bath & Body Works is a specialty home fragrance and fragrant body care retailer operating under the Bath & Body Works, C.O. Bigelow, and White Barn brands. The company generates most of its business in North America, with less than 5% of sales from international markets in fiscal 2021. For fiscal 2021, 72% of sales stemmed from the brick-and-mortar network (which is composed of more than 1,700 retail stores), up from 65% in 2020, as consumer shopping patterns began to return to normal. Future growth is expected from store reformatting, digital and international channels, as well as new category expansion.
Read more on BBWI →Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →